INTRODUCTION
============

Ailments of sleep have become one of the critical health problems giving detrimental effects on the quality of life of many people \[[@b1-kjim-2016-282],[@b2-kjim-2016-282]\]. Almost 30% of people worldwide complaint more than one of sleep problems \[[@b3-kjim-2016-282],[@b4-kjim-2016-282]\]. As a result, the current intake of hypnotics is estimated to generally range between 3% and 12%, doubling in elderly people \[[@b5-kjim-2016-282],[@b6-kjim-2016-282]\].

Hypnotics have an alleviating effect on insomnia but can have several adverse effects. Sleeping pills can worsen daytime somnolence as well as memory performances \[[@b7-kjim-2016-282]\]. For example, benzodiazepines (BZDs) have come to play a pivotal role for treating insomnia and are still widely prescribed to manage a sleep disturbance \[[@b8-kjim-2016-282]\]. However, BZDs are also known to have some side effects, such as confusion, amnesia, and tremors. Zolpidem is a non-BZD hypnotic drug used for the management of insomnia \[[@b9-kjim-2016-282]\] and can cause common adverse effects including headache, amnesia, and short-term memory loss \[[@b10-kjim-2016-282]\].

With respect to the risk of heart disease due to hypnotics, previous *in vitro* laboratory and animal studies have demonstrated a relationship between the use of hypnotics and increased risk of heart disease. Mailliet et al. \[[@b11-kjim-2016-282]\] reported that diazepam injection could induce adverse effects on cardiovascular parameters such as blood pressure and heart rate in rats. Another *in vitro* cell study showed that overdose of zolpidem might be associated with the risk of acquired long QT syndrome \[[@b12-kjim-2016-282]\]. For observational epidemiological studies, the relationship between hypnotics consumption and the risk of heart disease remains controversial. For example, in a 10-year follow-up research of 500 men \[[@b13-kjim-2016-282]\], there was no significant link between use of hypnotics and the risk of cardiovascular disease. However, another observational study \[[@b14-kjim-2016-282]\] found that use of BZD was associated with an increased risk of ischemic heart disease. In a cohort study in middle-aged people \[[@b15-kjim-2016-282]\], regular use of hypnotics was also strongly associated with increased mortality from coronary artery disease.

To date, there have been no quantitative meta-analyses regarding this topic. In the current study, we investigated the associations between use of hypnotics and the incidence of heart disease by performing a metaanalysis of observational epidemiologic studies such as case-control studies and cohort studies.

METHODS
=======

Data sources
------------

We reviewed the PubMed, EMBASE databases to establish potentially relevant articles related to hypnotics and heart disease (in January 1971 through in February 2016). We also searched the bibliographies of related articles to find additional publications. Common keywords used were as follows: "hypnotics," "sleep medication," "sleeping pill," "BZD," "zolpidem," and "zopiclone," "cardiovascular," "heart," "coronary," and "valvular." There were no restrictions on the language of publication.

Study selection
---------------

We chose studies which reported the effect of hypnotics on the risk or mortality from heart disease. Our meta-analysis was restricted to observational epidemiologic studies such as case-control studies and cohort studies. Included studies should demonstrate outcome measures with adjusted odds ratio (OR) or risk ratio (RR) and 95% confidence interval (CI). If data were duplicated or shared between more than one study, the first published study was included in the analysis. We did not include unpublished studies and abstracts that were only presented at academic conferences or were not published in peer-reviewed journals.

Three authors (Y.H.K., H.Y.S., and H.B.K.) assessed the eligibility of all studies retrieved from the databases following the above selection criteria independently. If arguments occurred between evaluators, they were resolved by discussion.

Assessment of methodological quality
------------------------------------

The methodological quality of the included studies was based on the Newcastle-Ottawa Scale (NOS) for assessing the quality of case-control studies and cohort studies in meta-analyses \[[@b16-kjim-2016-282]\]. A star system of the NOS ranges from 0 to 9 and consists of three subscales: selection of studies, comparability, and exposure. We considered a study awarded stars of more than a mean score of each study type as a high-quality study since the criteria for the high- or low-quality of a study have not been established.

Statistical analyses
--------------------

To calculate a pooled OR or RR with its 95% CI, we used the adjusted ORs or RRs and 95% CIs in each study, which report the association between hypnotics use (highest use vs. never use) and heart disease. We examined the heterogeneity in the results across studies using the Higgins *I*^2^, which measures the percentage of total variation across studies \[[@b17-kjim-2016-282]\]. The *I*^2^ was calculated as follows:
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where Q is Cochran's heterogeneity statistic and df, the degrees of freedom. Negative values of *I*^2^ were set to zero; the *I*^2^ results are between 0% (no observed heterogeneity) and 100% (maximal heterogeneity) \[[@b17-kjim-2016-282]\]. An *I*^2^ value greater than 50% was considered to indicate substantial heterogeneity.

When substantial heterogeneity was not observed, the fixed-effects model was implemented using the Woolf's (inverse variance) method for the pooled estimate. When substantial heterogeneity was observed, the random-effects model was implemented using the DerSimonian and Laird method for the pooled estimate \[[@b17-kjim-2016-282]\].

In the final analysis, we evaluated publication bias regarding the studies by using Begg's funnel plot and Egger's test. If publication bias existed, Begg's funnel plot would be asymmetrical or the *p* value would be less than 0.05 by Egger's test. We used the Stata SE version 13.0 (Stata Corp., College Station, TX, USA) for the statistical analysis.

RESULTS
=======

Identification of relevant studies
----------------------------------

A total of 495 articles were obtained by assessing two databases and hand-searching relevant bibliographies. We excluded 134 duplicated articles and additional 341 articles that did not achieve the inclusion criteria. We reviewed the full texts of the remaining 20 articles. We excluded 12 articles among these articles because of the following reasons: not relevant to our analysis (n = 5), insufficient data (n = 1), using data from pre-existing heart disease (n = 4), and using an acute biomarker as exposure (n = 2). The remaining eight studies (two case-control studies \[[@b18-kjim-2016-282],[@b19-kjim-2016-282]\] and six cohort studies \[[@b15-kjim-2016-282],[@b20-kjim-2016-282]-[@b24-kjim-2016-282]\]) were included in the final analysis ([Fig. 1](#f1-kjim-2016-282){ref-type="fig"}).

Characteristics of studies included in the final analysis
---------------------------------------------------------

We identified a total of eight observational studies including 1,355,793 participants (8,689 patient cases and 1,347,104 controls) \[[@b15-kjim-2016-282],[@b18-kjim-2016-282]-[@b24-kjim-2016-282]\]. In studies reporting age, the mean age was 56.2 years (range, 18 to 102). [Table 1](#t1-kjim-2016-282){ref-type="table"} demonstrates the general characteristics of the studies included in the final analysis. Based on the study design, two case-control studies (n = 918 cases) \[[@b18-kjim-2016-282],[@b19-kjim-2016-282]\] and six prospective cohort studies (n = 7,771 cases) \[[@b15-kjim-2016-282],[@b20-kjim-2016-282]-[@b24-kjim-2016-282]\] were included. Only one study \[[@b19-kjim-2016-282]\] collected hospital-based data. As for the types of heart disease, only one study \[[@b22-kjim-2016-282]\] demonstrated the risk of heart failure hospitalization, and other seven studies investigated the risk of cardiovascular disease occurrences \[[@b15-kjim-2016-282],[@b18-kjim-2016-282]-[@b21-kjim-2016-282],[@b23-kjim-2016-282],[@b24-kjim-2016-282]\]. Two studies examined the risk of heart diseases \[[@b19-kjim-2016-282],[@b22-kjim-2016-282]\], and six studies reported the mortality from heart disease \[[@b15-kjim-2016-282],[@b18-kjim-2016-282],[@b20-kjim-2016-282],[@b21-kjim-2016-282],[@b23-kjim-2016-282],[@b24-kjim-2016-282]\]. The studies were conducted in the following geographic regions: one study was performed in Canada (n = 462 cases) \[[@b21-kjim-2016-282]\], five in Europe (n = 1,346 cases) \[[@b15-kjim-2016-282],[@b18-kjim-2016-282],[@b20-kjim-2016-282],[@b22-kjim-2016-282],[@b23-kjim-2016-282]\], and two studies were performed in Asia (n = 6,881 cases) \[[@b19-kjim-2016-282],[@b24-kjim-2016-282]\].

Methodological quality of studies
---------------------------------

We evaluated the methodological quality of studies included in the final analysis based on the NOS. The range of quality scores was 6 to 8; the average score was 6.0 for case-control studies and 7.8 for cohort studies. The high-quality studies (score of 8 in only cohort studies) included five cohort studies \[[@b15-kjim-2016-282],[@b20-kjim-2016-282],[@b22-kjim-2016-282],[@b23-kjim-2016-282],[@b24-kjim-2016-282]\].

Use of hypnotics and the risk of or mortality from heart disease
----------------------------------------------------------------

As reported in [Fig. 2](#f2-kjim-2016-282){ref-type="fig"}, use of hypnotics was significantly associated with a decreased risk of or mortality from heart disease in the random-effects meta-analysis of all eight studies (OR/RR, 0.84; 95% CI, 0.79 to 0.89). [Table 2](#t2-kjim-2016-282){ref-type="table"} exhibits results from subgroup meta-analyses by various factors. On analyzing by the type of heart disease, there was a significant relationship between the use of hypnotics and cardiovascular disease, but not in heart failure. Based on the severity of heart disease, intake of hypnotics was associated with mortality from heart disease but not with risk of heart disease. With respect to gender, studies including both male and female subjects reported the same association but not in studies which enrolled only male subjects. The same association remained significant in high-quality studies but not in low-quality studies. Larger studies showed a tendency towards a more elevated estimate of association in terms of a significant decreased risk of or mortality from cardiovascular outcomes, compared to smaller studies.

Subgroup analysis based on the geographic region
------------------------------------------------

On stratifying by the geographic region, OR/RR was lowest in studies conducted in China/Taiwan compared to the studies conducted in Europe or Canada (*p* for studies conducted in Asia vs. non-Asian countries \< 0.01) ([Table 2](#t2-kjim-2016-282){ref-type="table"}). On dividing the geographic region into Western and Asian area, there was a positive relationship between the use of hypnotics and the risk of or mortality from heart disease in the Western area (pooled OR/RR, 1.21; 95% CI, 1.06 to 1.38 with a significant heterogeneity; *I*^2^, 63.3%).

Type of hypnotics and risk of or mortality from heart disease
-------------------------------------------------------------

The effects of hypnotics on risk of or mortality from heart disease were different according to the type of hypnotics ([Table 2](#t2-kjim-2016-282){ref-type="table"}). Zolpidem users have a tendency for decreased risk of heart disease (OR/RR, 0.71; 95% CI, 0.55 to 0.92), but BZD use showed the possibility of increased risk of or mortality from heart disease (OR/RR, 1.80; 95% CI, 1.77 to 1.84).

Publication bias
----------------

No publication bias was found in the selected studies (Begg's funnel plot was symmetric; Egger's test, *p* for bias = 0.14).

DISCUSSION
==========

We found that the use of hypnotics was associated with a decreased risk of or mortality from heart disease in the current meta-analysis of observational epidemiological studies especially for Asia people.

There are several possible explanations for the association. First, previous systematic reviews of epidemiologic observational studies reported that insomnia was positively related with a risk of or mortality from cardiovascular disease \[[@b25-kjim-2016-282]\]. In addition, there are emerging evidences that anxiety could be one of the important causes for the development of coronary artery disease and mortality from cardiac diseases \[[@b26-kjim-2016-282],[@b27-kjim-2016-282]\]. In an animal study in which zopiclone or zolpidem were administrated to rat, zopiclone exhibited a lowering effect on anxiety behavior \[[@b28-kjim-2016-282]\]. Therefore, it is possible that hypnotics can lower the risk of coronary artery disease by alleviating insomnia or anxiety.

Second, as a considerable part of incidence of and/or mortality from heart disease can be attributable to many confounding factors such as smoking, alcohol, hypertension, diabetes, dyslipidemia, obesity, physical inactivity, and family history of heart disease, they could underlie the relationship \[[@b29-kjim-2016-282]-[@b31-kjim-2016-282]\]. In this meta-analysis, seven studies \[[@b15-kjim-2016-282],[@b18-kjim-2016-282]-[@b23-kjim-2016-282]\] included smoking status as a confounding factor, and the significant negative association disappeared (OR/RR, 1.11; 95% CI, 0.98 to 1.25). And there can be another undetected confounding factors which may contribute to the association between the use of hypnotics and risk of heart disease.

Our meta-analysis showed that the BZDs can increase the risk of or mortality from heart diseases unlike non-BZDs. Our finding is coherent with the result in the study by Lapane et al. \[[@b32-kjim-2016-282]\] in which ischemic heart disease occurrence was two times in BZD users than non-users. The possible detrimental effects of BZD on heart disease also can be seen at a laboratory study which looked at the effects of BZD on heart rate. Use of triazolam or flurazepam as hypnotics resulted in a significant elevation of heart rate that was existing for up to 4 hours during sleep \[[@b33-kjim-2016-282]\]. Hypotension can often be observed in subjects who overuse BZDs than average \[[@b34-kjim-2016-282]\]. One possible mechanism by which BZD intake can be connected to the risk of heart disease is infection with virus. When a total of 1,682 people who had no HIV at baseline were followed for about 80 months \[[@b35-kjim-2016-282]\], BZD use was significantly associated with an increased rate of HIV seroconversion (adjusted risk ratio, 1.50; 95% CI, 1.01 to 2.24). A cross-sectional study enrolling a total 354 subjects \[[@b36-kjim-2016-282]\] showed that cardiovascular disease occurrence was higher in HIV-infected patients than HIV-negative subjects. Another virus which can connect use of hypnotics and the risk of heart disease can be hepatitis C virus (HCV). In a prospective study of the AIDS Care Cohort and Vancouver Injection Drug Users Study (VIDUS) cohorts followed-up from 1996 to 2013 in Canada \[[@b37-kjim-2016-282]\], there was a significant relationship between BZD use and seroconversion of HCV. Chronic infection with HCV can play a pivotal role for growing prevalence for ischemic heart disease, independent of the conventional risk factors for cardiovascular events or the severity of liver disease \[[@b38-kjim-2016-282]\].

We found that there was a racial difference in the effect of hypnotics on risk of or mortality from heart disease. In a report from the Multiethnic Study of Atherosclerosis (MESA) \[[@b39-kjim-2016-282]\], the prevalence of calcification measured by coronary calcium score in computed tomography was 70% in white men, 59% in Chinese men after adjusting conventional risk factors. Japanese also had higher HDL cholesterol levels which is related with decreased risk of cardiovascular disease than whites \[[@b40-kjim-2016-282]\]. The frequency of the T allele for hepatic lipase which is associated with higher level of HDL cholesterol as well as lower level of triglycerides was three times higher in Japanese than in Caucasians. The defensive cardiovascular mechanisms of hypnotics especially observed in Asian is not well known and need additional explorations.

Our meta-analysis has several strengths. We investigated a large number of subjects with a long time of follow-up. All of included studies were population-based with the exception of the study by Zhou et al. \[[@b19-kjim-2016-282]\]. This gives a high statistical power for examining the relationship between hypnotics use and risk of heart disease. Another advantage of our study is that no significant publication bias was observed.

Our study has several limitations. First, we only included observational epidemiological studies because few randomized controlled trials have been published on this topic so far. In general, case-control studies are more susceptible to biases, such as selection bias and recall bias than cohort studies. In addition, cohort studies have a lower level of evidence than randomized controlled trials. Thus, our meta-analysis does not provide the high level of evidence. Second, definitions of use of hypnotics in each study were fairly heterogeneous. We used the highest and lowest levels of hypnotics use about the exposure definition in most studies. This could have led to heterogeneity. Third, most of data were acquired from questionnaires; hence, the possibility of encountering bias due to misinterpretation of the question can exist. Finally, we found significant heterogeneity across studies, which may have resulted from differences in study designs, sample sizes, heart disease measures, analysis strategies, and participants' characteristics.

KEY MESSAGE
===========

1\. The association between hypnotics intake and the risk of heart disease remains controversial in several observational epidemiological studies.

2\. We investigated the associations by performing a meta-analysis.

3\. Our meta-analysis of observational epidemiological studies found that use of hypnotics was associated with a decreased risk of or mortality from heart disease.

No potential conflict of interest relevant to this article was reported.
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![Use of hypnotics and risk of heart disease by study design in a meta-analysis of epidemiologic studies (n = 8). OR, odds ratio; CI, confidence interval.](kjim-2016-282f2){#f2-kjim-2016-282}

###### 

General characteristics of the studies included in the final analysis

  Study                                             Type of study                         Country   Years enrolled   Population (sex, age)                                              Type of outcome                 Definition ofhypnot-ics use (longest vs. shortest category)   OR/RR (95% Cl)       Adjusted variable
  ------------------------------------------------- ------------------------------------- --------- ---------------- ------------------------------------------------------------------ ------------------------------- ------------------------------------------------------------- -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Merlo et al. (1996) \[[@b18-kjim-2016-282]\]      Case-control study                    Sweden    1982-1983        54 Cases among 496 cohorts (men, 68 years)                         IHD death                       Hypnotics use vs. never-use                                   0.80 (0.30--2.10)    Systolic and diastolic blood pressure, serum cholesterol, smoking, history of IHD, cancer, diabetes, high alcohol consumption, and other disease (TB, Parkinson disease, rheumatoid arthritis, osteoarthritis, liver, renal, and mental diseases)
  Mallon et al. (2002) \[[@b20-kjim-2016-282]\]     Prospective cohort study              Sweden    1983-1995        71 Cases among 1, 870 cohorts (men & women, average 56.0 years)    CAD death                       Habitual sleeping pill use vs. never-use                      2.20 (0.70--7.10)    Age (in 5-year strata), not married, living alone, smoking, BMI \> 28, hypertension, cardiac disease, respiratory disease, diabetes, joint pain, gastrointestinal disease, depression, sleep duration \< 6 hours, sleep duration \> 8 hours, DIS, DMS, habitual snoring, habitual sleeping pill usage, and urogenital disease
  Mallon et al. (2009) \[[@b15-kjim-2016-282]\]     Prospective cohort study              Sweden    1983-2003        125 Cases among 1, 750 cohorts (men, 30--65 years)                 CAD death                       Regular hypnotics use vs. never-use                           4.55 (1.65--12.58)   5-Year strata, regular hypnotic usage, DIS, DMS, SL \> 45 minutes, TST \< 6 hours, smoking, habitual snoring, BMI, heart disease, hypertension, diabetes, asthma, depression, and living alone
  Belleville (2010) \[[@b21-kjim-2016-282]\]        Prospective cohort study              Canada    1994-2009        462 Cases and 14, 117 cohorts (men & women, mean age 44.1 years)   Circulatory disease death       Hypnotics: ever-use vs. never-use                             1.32 (1.11--1.56)    Age, sex, racial background, education, employment status, family income, marital status, level of physical activity, smoking and drinking habits, and physical health
  Rod et al. (2011) \[[@b22-kjim-2016-282]\]        Prospective cohort study              Denmark   1991-2007        8, 670 Cohorts (men & women, mean age 57.0 years)                  Heart failure hospitalization   Daily intake of hypnotics vs. never-use                       1.10 (0.70--1.75)    Age, education, family history of myocardial infarction, systolic blood pressure, diastolic blood pressure, total cholesterol, diabetes mellitus, physical activity, tobacco smoking, body mass index, and alcohol consumption
  Zhou et al. (2012) \[[@b19-kjim-2016-282]\]       Case-control study (hospital based)   China                      864 Cases and 1, 008 controls (men & women, mean age 61.0 years)   CAD                             Non-benzodiazepine ever-use vs. neveruse                      0.73 (0.54--0.98)    Age, sex, BMI, hypertension, diabetes, dyslipidemia, smoking, and physical activity
  Jaussent et al. (2013) \[[@b23-kjim-2016-282]\]   Prospective cohort study              France    1999-2011        385 Cases among 6, 696 cohorts (men and women, ≥ 65 years)         CAD death                       Hypnotics ever-use vs. never-use                              0.92 (0.71--1.20)    Age, gender, study center, high level of education, confinement, alcohol intake, smoking status, history of cardio-cerebrovascular disease, respiratory disease, Mini Mental State Examination score, body mass index, hypertension and diabetes mellitus, depressive symptoms, antidepressants use, Spielberger trait anxiety score, excessive daytime sleepiness, and number of insomnia complaints
  Lan et al. (2015) \[[@b24-kjim-2016-282]\]        Retrospective cohort study            Taiwan    2000-2009        6, 017 Cases among 1, 320, 322 cohorts (men and women, 18 years)   CAD death                       Zolpidem: ever-use vs. never-use                              0.76 (0.71--0.82)    Age, gender, level of main medical facility, area of residence, cDDD, and Elixhauser comorbidities

OR, odds ratio; RR, relative ratio; CI, confidence interval; IHD, ischemic heart disease; TB, tuberculosis; CAD, coronary artery disease; BMI, body mass index; DIS, difficulties initiating sleep; DMS, difficulties maintaining sleep; SL, sleep latency; TST, total sleep time; cDDD, cumulative defined daily dose.

###### 

Association between hypnotics use and the risk of or mortality from heart disease in subgroup meta-analyses

  Factor                                                                                                                                         No. of studies   Summary OR/RR (95% CI)   Heterogeneity, *I*^2^ (%)   Model used
  ---------------------------------------------------------------------------------------------------------------------------------------------- ---------------- ------------------------ --------------------------- ----------------
  All \[[@b15-kjim-2016-282],[@b18-kjim-2016-282]-[@b24-kjim-2016-282]\]                                                                         8                0.84 (0.79--0.89)        86.1                        Random-effects
  Type of heart disease                                                                                                                                                                                                
   Cardiovascular disease \[[@b15-kjim-2016-282],[@b18-kjim-2016-282]-[@b21-kjim-2016-282],[@b23-kjim-2016-282],[@b24-kjim-2016-282]\]           7                0.84 (0.78--0.89)        87.8                        Random-effects
   Heart failure \[[@b22-kjim-2016-282]\]                                                                                                        1                1.10 (0.70--1.75)        NA                          NA
  Severity of heart disease                                                                                                                                                                                            
   Risk \[[@b19-kjim-2016-282],[@b22-kjim-2016-282]\]                                                                                            2                0.82 (0.64--1.06)        53.7                        Random-effects
   Mortality \[[@b15-kjim-2016-282],[@b18-kjim-2016-282],[@b20-kjim-2016-282],[@b21-kjim-2016-282],[@b23-kjim-2016-282],[@b24-kjim-2016-282]\]   6                0.84 (0.79--0.90)        89.6                        Random-effects
  Sex                                                                                                                                                                                                                  
   Male only \[[@b15-kjim-2016-282],[@b18-kjim-2016-282]\]                                                                                       2                1.84 (0.91--3.71)        83.0                        Random-effects
   Male & female \[[@b19-kjim-2016-282]-[@b24-kjim-2016-282]\]                                                                                   6                0.84 (0.78--0.89)        87.4                        Random-effects
  Region                                                                                                                                                                                                               
   America \[[@b21-kjim-2016-282]\]                                                                                                              1                1.32 (1.11--1.56)        NA                          NA
   Europe \[[@b15-kjim-2016-282],[@b18-kjim-2016-282],[@b20-kjim-2016-282],[@b22-kjim-2016-282],[@b23-kjim-2016-282]\]                           5                1.05 (0.85--1.30)        63.3                        Random-effects
   Western \[[@b15-kjim-2016-282],[@b18-kjim-2016-282],[@b20-kjim-2016-282]-[@b23-kjim-2016-282]\]                                               6                1.21 (1.06--1.38)        63.3                        Random-effects
   Asia \[[@b19-kjim-2016-282],[@b24-kjim-2016-282]\]                                                                                            2                0.76 (0.71--0.81)        0                           Fixed-effect
  Duration of zolpidem use, yr                                                                                                                                                                                         
   0--5                                                                                                                                          1                0.91 (0.63--1.32)        NA                          NA
   5--10                                                                                                                                         1                0.64 (0.38--0.97)        NA                          NA
   \> 10                                                                                                                                         1                0.42 (0.18--0.85)        NA                          NA
  Type of hypnotics                                                                                                                                                                                                    
   Zolpidem \[[@b19-kjim-2016-282],[@b23-kjim-2016-282]\]                                                                                        2                0.71 (0.55--0.92)        0                           Fixed-effect
   Benzodiazepine \[[@b19-kjim-2016-282],[@b23-kjim-2016-282],[@b24-kjim-2016-282]\]                                                             3                1.80 (1.77--1.84)        88.3                        Random-effects
  Case-control study design                                                                                                                                                                                            
   Population-based \[[@b15-kjim-2016-282],[@b18-kjim-2016-282],[@b20-kjim-2016-282]-[@b24-kjim-2016-282]\]                                      7                0.84 (0.79--0.90)        87.9                        Random-effects
   Hospital-based \[[@b19-kjim-2016-282]\]                                                                                                       1                0.73 (0.54--0.98)        NA                          NA
  Methodological quality                                                                                                                                                                                               
   High quality \[[@b15-kjim-2016-282],[@b20-kjim-2016-282],[@b22-kjim-2016-282]-[@b24-kjim-2016-282]\]                                          5                0.79 (0.73--0.84)        78.7                        Random-effects
   Low quality \[[@b18-kjim-2016-282],[@b19-kjim-2016-282],[@b21-kjim-2016-282]\]                                                                3                1.13 (0.98--1.31)        83.3                        Random-effects
  Sample size                                                                                                                                                                                                          
   \< 5,067 subjects \[[@b15-kjim-2016-282],[@b18-kjim-2016-282],[@b20-kjim-2016-282],[@b23-kjim-2016-282]\]                                     4                0.88 (0.68--1.16)        78.6                        Random-effects
   \> 5,068 subjects \[[@b19-kjim-2016-282],[@b21-kjim-2016-282],[@b22-kjim-2016-282],[@b24-kjim-2016-282]\]                                     4                0.84 (0.78--0.89)        91.7                        Random-effects

OR, odds ratio; RR, risk ratio; CI, confidence interval; NA, not applicable.
